Synlogic Inc · OTC:SYBX

Synlogic — Investor Presentation (March 2021)

46 slides from Synlogic's investor presentation, Mar 25, 2021

  1. Slide 1: Bringing the Transformative Power of Synthetic Biology to Medicine

    Bringing the Transformative Power of Synthetic Biology to Medicine Corporate Presentation March 2021 Exhibit 99.3

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in

  3. Slide 3: Clinical proof of concept data expected across multiple programs in 2021

    SYNB1891 in Solid Tumors Monotherapy target engagement, meaningful pharmaco-dynamic effects, good safety Combination with anti-PD1 and dose escalation ongoing Metabolic programs: Two PoC opportunities Immunomodulation Clinical proof of concept data expected across multiple programs in 2021 2021 data

  4. Slide 4: A new class of medicines

    A new class of medicines Enabling engine of synthetic biology, manufacturing and translational capabilities Creates multiple product opportunities Robust pipelines Rare metabolic therapies that consume toxic metabolites from the GI tract Therapies that leverage the ability of bacteria to interact wi

  5. Slide 5: Robust pipelines with meaningful catalysts

    Exploratory Preclinical IND-Enabling Studies Phase 1 Phase 2 Phenylketonuria (PKU) SYNB1618 Vaccines & Other Inflammatory Immuno-Oncology (IO) Solid Tumors SYNB1891 Inflammatory Bowel Disease Enteric Hyperoxaluria SYNB8802 SYNB1618 Undisclosed Metabolic Program #1 Undisclosed Metabolic Program #2 Po

  6. Slide 6: Synthetic Biotic medicines: a novel approach to metabolic disease

    Rationale High unmet need across inherited and acquired metabolic diseases Multiple large and underserved markets Diseases with known pathophysiology Dietary intervention validates GI approach Bacteria evolved to survive in the GI tract Ability to deploy multiple enzyme pathways Drug-like approach w

  7. Slide 7: Applying Synthetic Biotic medicines to PKU and Enteric Hyperoxaluria

    Applying Synthetic Biotic medicines to PKU and Enteric Hyperoxaluria Unique Advantages Platform Proof of Mechanism Validated Biology Unmet Medical Need Phenylketonuria (PKU) Enteric Hyperoxaluria (HOX) Many patients unable to control Phe ~30% BH4 oral therapy response rates High kidney disease risk

  8. Slide 8: Phenylketonuria (PKU)

    Phenylketonuria (PKU) Current and emerging treatment options leave many patients behind SYNB1618 demonstrates potential to lower Phe in PKU patients Phase 2 Phe-lowering trial initiated

  9. Slide 9: Patient need: parents expect their children to reach full potential

    Patient need: parents expect their children to reach full potential Reality: 25% – 65% of patients still struggle to maintain blood Phe within target range Historically Prospect of severe mental disability and institutionalization. Parents wanted PKU child to avoid institutionalized care before adul

  10. Slide 10: An innovative approach in area of high unmet medical need

    An innovative approach in area of high unmet medical need Our approach Oral therapy, 3 x day with meals Consume Phe in the GI Tract Reduce plasma Phe Synlogic has initiated a Ph2 Study in PKU patients (SynPheny) Meaningful biomarker-driven patient outcomes Lower blood Phe Addition of more natural pr

  11. Slide 11: Significant market opportunity, large unmet need

    Significant market opportunity, large unmet need, with potential for new products to capture share Disease Goal Patients Product Use Monotherapy Combination Prescribed with Kuvan Out of Phe Control In Phe control Lower blood Phe Addition of more natural protein/day Adults ~12,300 U.S. 65% out of Phe

  12. Slide 12: SYNB1618 is uniquely positioned to address those needs

    Includes 7,500 “lost to follow up” SYNB1618 is uniquely positioned to address those needs Marketed Marketed Phase 1/2 Phase 3 Mechanism does not depend on genotype Appropriate for pediatrics and adults Benign safety profile, no systemic exposure Oral administration Phase 2 SYNB1618 Marketed Developm

  13. Slide 13: Solid oral SYNB1618 reduced Phe and elevated biomarkers in Ph1

    Solid oral SYNB1618 reduced Phe and elevated biomarkers in Ph1 Achieved Proof of Mechanism: SYNB1618 consumed D5 Phe in GI tract & lowered plasma D5 Phe Data are means and 90% CI D5 Phe Converted to D5 TCA Plasma D5 Phe Blunted D5 TCA Converted to D5 HA

  14. Slide 14: SynPheny-1 design enables Proof of Concept

    SynPheny-1 design enables Proof of Concept 3 days Dose 1 1e11 Dose 3 1e12 Dose 4 2e12 7 days Diet run-in 6 days 2 days D5-Phe AUC Baseline Fasting Phe Dose 2 3e11 3 days D5-Phe AUC Day 14 Fasting Phe TRIAL DESIGH Plasma Phe lowering in fasted state at 1e12 live cells over 7 days Post meal D5-Phe AUC

  15. Slide 15: Opportunity for multiple clinically relevant outcomes

    Opportunity for multiple clinically relevant outcomes Study powered for 20% reduction in labelled plasma Phe, providing clinically meaningful endpoint for patients without other treatment options Learning Opportunities in current SynPheny study Reduction in labelled plasma Phe after a meal challenge

  16. Slide 16: Enteric Hyperoxaluria (HOX)

    Enteric Hyperoxaluria (HOX) Enteric Hyperoxaluria results in significant, irreversible, and progressive kidney damage SYNB8802 offers potential for best-in-class urinary oxalate lowering SYNB8802 proof of mechanism established: proof of concept on track for 2021 data read out

  17. Slide 17: Hyperoxaluria: Primary vs. Enteric

    Hyperoxaluria: Primary vs. Enteric Number of Patients Affected Primary Hyperoxaluria Enteric Hyperoxaluria Pathology Rare genetic condition Dietary oxalate hyperabsorption Onset Pediatric Adult Trigger Genetic liver enzyme deficiency Underlying insult to bowel: including IBD, bariatric surgery, othe

  18. Slide 18: Enteric Hyperoxaluria: An important cause of renal failure

    33 yo woman with bowel resection resulting in severe hyperoxaluria (135 mg/day) Clinical course punctuated by: Recurrent kidney stones Progressive renal failure Hemodialysis Renal transplant x 1 Recurrent renal failure Hemodialysis Renal transplant x 2 Enteric Hyperoxaluria: An important cause of re

  19. Slide 19: An innovative approach in area of high unmet medical need

    An innovative approach in area of high unmet medical need Our approach Oral therapy Consume Oxalate the GI Tract Reduce Oxalate in the urine Differentiation from other approaches Ph 1B Proof of Concept in Enteric Hyperoxaluria patients (Roux-en-Y population) initiated Stomach Colon Consumes oxalate

  20. Slide 20: Absorbs oxalate throughout GI tract, esp. in colon

    Absorbs oxalate throughout GI tract, esp. in colon Dietary Oxalate Stomach Small intestine Colon Oxalate absorption Healthy state Disease state Healthy people absorb ~10% of dietary oxalate, mostly via stomach and small intestine Patients absorb ~20-30% of dietary oxalate, through entire GI tract in

  21. Slide 21: Ph1 design provides POC opportunity in 2021

    Ph1 design provides POC opportunity in 2021 Dietary hyperoxaluria model is translationally relevant to patient population Phase 1A Dietary Hyperoxaluria (Healthy Volunteers) Multiple Ascending Dose High oxalate & low calcium diet run-in Induce dietary hyperoxaluria N = 45 subjects Endpoints Primary:

  22. Slide 22: High oxalate diet successfully elevated UOx levels in HV

    High oxalate diet successfully elevated UOx levels in HV Historically Uox in HV is <40 mg/24h. Examples: Langman 2018, (27 mg), Quintero 2020, (19.8mg), Captozyme 2018 (28 mg). Mean +/- SD shown. American diet contains approx. 200-250 mg oxalate/day HV subjects were given a high oxalate, low calcium

  23. Slide 23: Dose-responsive and reproducible Uox lowering demonstrated

    Dose-responsive and reproducible Uox lowering demonstrated Efficacy Analysis (% Change from Baseline in 24h UOx over Pbo) 600mg Daily Oxalate 400mg Daily Oxalate Lower is better Lower is better LS mean change over Placebo, +/- 90% CI, all days baseline and treated

  24. Slide 24: SYNB8802 3e11 live cells dose advancing to Ph1B in patients

    SYNB8802 3e11 live cells dose advancing to Ph1B in patients LS mean change over Placebo, +/- 90% std error of measurement, all days; and 24hr UOx after 5 days of dosing, +/- 90% std error of measurement. 600mg daily oxalate. Change in UOx UOx Levels Clinically meaningful lowering of urinary oxalate

  25. Slide 25: Opportunity for multiple clinically relevant outcomes in Phase1B

    Opportunity for multiple clinically relevant outcomes in Phase1B Potential to demonstrate meaningful urinary oxalate lowering in patients with active disease Learning opportunities in Phase 1 SYNB8802 has established urinary oxalate lowering in Dietary Hyperoxaluria (HV) model Potential for urinary

  26. Slide 26: SYNB8802 Summary: 3e11 live cells moving into patients

    SYNB8802 Summary: 3e11 live cells moving into patients SYNB8802 was generally well tolerated in healthy volunteers. No serious or systemic adverse events. Most frequent AEs mild or moderate, transient, and GI-related Dose responsive changes in urinary oxalate levels were observed with a significant

  27. Slide 27: Synlogic is entering a data rich period in the clinic

    Synlogic is entering a data rich period in the clinic Robust portfolio with significant clinical readouts in 2021 H1 2021 H2 2021 PKU Enteric Hyperoxaluria Immuno-Oncology SYNB1891 Ph1 Arm 2 combination read-out SYNB1618 Ph2 SynPheny proof of concept read-out SYNB8802 Ph1A study in HV read-out SYNB8

  28. Slide 28: Balance Sheet and Statement of Operations

    Balance Sheet (unaudited) 31 Dec 2020 31 Dec 2019 Cash, Cash Equivalents, and Marketable Securities $100.4 M $127.1M Statement of Operations (unaudited) 31 Dec 2020 31 Dec 2019 31 Dec 2020 31 Dec 2019 R&D Expenses $11.4 M $11.3 M $47.5 M $41.9 M G&A Expenses $3.3 M $3.5 M $13.5 M $14.7 M Net Loss $(

  29. Slide 29: Experienced leadership team and Board

    Collaborators Board of Directors Experienced leadership team and Board Peter Barrett, Chair Atlas Venture Mike Burgess Turnstone Biologics Michael Heffernan Collegium Patricia Hurter Lyndra Therapeutics Lisa Kelly-Croswell Boston Medical Center Health System Chau Khuong Orbimed Advisors Nick Leschly

  30. Slide 30: Focus on Immuno-Oncology

    Focus on Immuno- Al A gh Oncology He ie N an synlogic © 2021 SYNLOGIC. ALL RIGHTS RESERVED. | 30

  31. Slide 31: Synthetic Biotic medicines are well-suited to regulating the immune system

    Cross-talk between bacteria and Immune System Unmet Medical Need Unique Advantages Platform attributes Why immunology? Why Synthetic Biotic medicine? Rationale Need for novel treatments which upregulate (I/O) or downregulate (IBD) immune responses Immune system has evolved to recognize bacteria Bact

  32. Slide 32: Immuno-Oncology SYNB1891

    Immuno-Oncology SYNB1891 potential for improved efficacy relative to other STING approaches SYNB1891 monotherapy demonstrated meaningful pharmacodynamic effects Phase 1 in combination with Tecentriq initiated: Data will be available in 2021

  33. Slide 33: SYNB1891 induces potent anti-tumoral effects

    SYNB1891 induces potent anti-tumoral effects d1 SYNB1891 109 CFU, i.t. or 50 ug ADU-S100, i.t. B16-F10 tumors ~100 mm3, randomize groups d7 d4 d32 d1 109 CFU, i.t. (SYNB or SYNB1891) B16-F10 tumors ~100 mm3, randomize groups d7 d4 d21 = Dose = Dose EcN EcN SM STING agonist SYNB1891 superior to wild

  34. Slide 34: Phase design: multidose tolerability, IT mono and combo

    Phase 1 design: multidose tolerability, IT mono and combo Arm 1: Monotherapy Cohorts Arm 2: Combination Cohorts - Atezolizumab Sentinel Patient Day 7 safety Eval Patient 2 & 3 Safety Evaluation Repeat for each cohort Arm 1 Cohort 4 Starting dose Arm 1 Cohort 3 level (1x107) Sentinel Patient Day 7 sa

  35. Slide 35: SYNB1891 advanced into combo therapy arm with Tecentriq

    SYNB1891 advanced into combo. therapy arm of Ph. 1 with Tecentriq SYNB1891 is safe and well-tolerated as an intratumoral injection with no dose limiting toxicities or infections to date Combination therapy data will be available in late 2021 Monotherapy dose escalation will continue in parallel to c

  36. Slide 36: Engineering Synthetic Biotic Medicines

    Engineering Synthetic Biotic Medicines

  37. Slide 37: Reusable parts enable rapid iteration of rationally designed prototypes

    Reusable parts enable rapid iteration of rationally designed prototypes Non-pathogenic bacterial chassis Programable, controllable engineering Drug-like properties Does not colonize No in vivo reproduction or risk of genetic drift Inducer-Promoter Switch Effector Design Safety Features E. coli Nissl

  38. Slide 38: Synthetic Biotic Platform accelerates pathway into the clinic

    Synthetic Biotic Platform accelerates pathway into the clinic Validated biology Unmet medical need Unique SYBX advantages Target selection Enabling Engine Internal GMP manufacturing Modular SynBio components Translational, clinical and regulatory Deep synthetic biology expertise Resulting portfolio

  39. Slide 39: Synthetic Biotic Platform is enabling engine for drug development

    Synthetic Biotic Platform is enabling engine for drug development Rapid pipeline expansion possible with reusable engineering >200 humans dosed with Synthetic Biotic medicines 4 INDs opened with the U.S. FDA Supportive regulatory feedback from global agencies Safe chassis organism (>100 years of hum

  40. Slide 40: Versatile platform enables diverse therapeutic strategies

    Small molecule production Metabolite consumption Effector secretion Surface display Versatile platform enables diverse therapeutic strategies for range of diseases Synthetic Biotic Platform

  41. Slide 41: Component library of parts

    Component Library of parts Therapeutic strategy Metabolite consumption, small molecule production, effector secretion or surface display Bacterial Chassis Probiotic: Decades of human use & safety data Effector(s) Proteins for activity: Can generate biomarkers Pump Transports metabolites or proteins

  42. Slide 42: SYNB1618 Design

    Component SYNB1618 Design Therapeutic strategy Metabolite consumption: Built from Synthetic Library Specifically to Consume Phe Bacterial Chassis E. coli Nissle Effector(s) PAL3 Enzyme: Degrades Phe to TCA (measurable biomarker of activity) LAAD Enzyme: Alt. Phe-consuming pathway Pump PheP: Pumps Ph

  43. Slide 43: SYNB8802 Design

    Component SYNB8802 Design Therapeutic strategy Metabolite consumption: Engineered to Convert Oxalate to Formate for the Treatment of Enteric Hyperoxaluria Bacterial Chassis E. coli Nissle Effector(s) OxdC and associated components: Catalyzes conversion of oxalate to formate Pump OxLT: Pumps oxalate

  44. Slide 44: Rapid progress to proof of concept: SYNB8802 case study

    Preclinical IND PoC SYNB1618 SYNB8802 Product Candidate Proprietary platform Target selection Reusable parts enables rapid progress to proof of concept: SYNB8802 case study 10 months from target selection to IND Planning Target with low toxic metabolite load, validated biology Research & Synthetic B

  45. Slide 45: SYNB1891 Design

    Component SYNB1981 Design Therapeutic strategy Small molecule production: Leveraging the ability of bacteria to interact with the immune system to turn a cold tumor hot Bacterial Chassis E. coli Nissle: Targeting to antigen presenting cells in the tumor microenvironment. Innate immune activation Eff

  46. Slide 46: BINNEY ST., #402, CAMBRIDGE, MA 02142 TEL: 617-401-9975 WEB: WWW.SYNLOGICTX.COM EMAIL: [email protected] © SYNLOGIC.

    301 BINNEY ST., #402, CAMBRIDGE, MA 02142 TEL: 617-401-9975 WEB: WWW.SYNLOGICTX.COM EMAIL: [email protected] © SYNLOGIC. ALL RIGHTS RESERVED.

Synlogic — Investor Presentation (March 2021) on 6ix